Antiangiogenic therapy in oncology: current status and future directions (Q38725587)

5 September 2017

1 reference

title

Antiangiogenic therapy in oncology: current status and future directions (English)

1 reference

5 September 2017

main subject

angiogenesis inhibitor

1 reference

1

1 reference

5 September 2017

4

1 reference

5 September 2017

Robert Kerbel

2

1 reference

5 September 2017

Lee M Ellis

series ordinal

3

1 reference

5 September 2017

language of work or name

English

0 references

publication date

4 February 2016

1 reference

5 September 2017

1 reference

5 September 2017

volume

388

1 reference

5 September 2017

issue

10043

1 reference

5 September 2017

page(s)

518-529

1 reference

Tumor angiogenesis: therapeutic implications

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

1 reference

7 January 2021

Angiogenesis as a therapeutic target

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

The angiogenic process as a therapeutic target in cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

NOTCH decoys that selectively block DLL/NOTCH or JAG/NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor growth

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Treatment selection in metastatic renal cell carcinoma: expert consensus

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Molecular mechanisms and clinical applications of angiogenesis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

VEGF and the quest for tumour angiogenesis factors

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Phase I study of recombinant human endostatin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Practices and pitfalls of mouse cancer models in drug discovery.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Mouse models of advanced spontaneous metastasis for experimental therapeutics

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Patient-derived tumour xenografts as models for oncology drug development

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Mechanism of tumour vascularization in experimental lung metastases

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Angiogenesis in primary lung cancer and lung secondaries

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Improved survival with bevacizumab in advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

RET revisited: expanding the oncogenic portfolio

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

A randomized trial of bevacizumab for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant pros

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Intra-tumoural microvessel density in human solid tumours.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Pathways mediating resistance to vascular endothelial growth factor-targeted therapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Effect of p53 status on tumor response to antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b Gr1 myeloid cells.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Serpins promote cancer cell survival and vascular co-option in brain metastasis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

VEGF inhibition beyond tumour progression

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

The parallel lives of angiogenesis and immunosuppression: cancer and other tales

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

Bevacizumab plus ipilimumab in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(15)01088-0

7 January 2021

10.1016/S0140-6736(15)01088-0

Identifiers

DOI

1 reference

5 September 2017

1 reference